Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 1,401–1,500 of 1,871
Active lupus nephritis is an orphan disease
Patricio-Liébana, M., Soler, M. J., Bruchfeld, A. N., et al. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag056
GLP-1 receptor agonists: The good, the bad, and the ugly—A comprehensive guide for NPs
Rodriguez, M. E., Lavell, J., & Foreman, R. M. (2026) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000430
VII. Therapeutic Strategies for Diabetic Kidney Disease
Kawanami, D. (2025) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.114.656
Nassiri, S., Handoko, M. L., van de Bovenkamp, A. A., van Empel, V. P. M., van Raalte, D. H., & Eringa, E. C. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10671-x
Delivery devices and container closure systems for co-formulated and co-administered biologics
Zhou, M., Duffy, K. H., Mitchener, C., Shi, G. H., & Collins, D. S. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag034
Sklepinski, S. M., Herrin, J. S., Neumiller, J. J., Polley, E. C., SWARNA, K. S., Deng, Y., Galindo, R. J., Umpierrez, G. E., Ross, J. S., Brito, J. P., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc26-0025
Pantalone, K. M., Singh, R. K., Wu, A., Betts, K. A., Chen, Y., Farag, Y. M. K., Beeman, S. C., Du, Y., Kong, S. X., Williamson, T. E., et al. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.24302 · Cited by 1
Zayan, T. A., & Khafagy, H. A. (2026) · World Advances in Renal Medicine · doi:10.25259/warm_15_2026
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00131-3
A Comprehensive Approach to Managing People With Diabetes and Chronic Kidney Disease
Cutrell, S., Zbyrak, V., Wheeler, S. E., Bucheit, J. D., & Khan, R. W. (2024) · ADCES in Practice · doi:10.1177/2633559x241280305
Møller, A. L., Thöni, S., Keller, F., Sharifli, S., Genovese, F., Karsdal, M. A., Rasmussen, D. G. K., & Mayer, G. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00526.2025 · Cited by 1
Kuehn, B. M. (2025) · Kidney News · doi:10.62716/kn.000322025
2025 Nutrition Science & Communications Forum: Summary
Steiber, A. L., Paulsen, E., & Brown, N. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156324
Tsai, S.-F., Liu, W.-J., Lin, Y.-J., & Lee, C.-L. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01118-z
“…therapies such as renin–angiotensin system inhibitors [4–6], sodium–glucose co-transporter 2 inhibitors [7, 8], and finerenone [9, 10] and GLP-1 receptor agonists [11], life-style modification (including dietary approaches) (from 2020 KDOQI guideline) [12] remains a cornerstone of CKD management.”
Li, M. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1926629
“FLOW demonstrated that semaglutide reduces clinically important kidney outcomes and cardiovascular death in patients with type 2 diabetes and chronic kidney disease (29).”
Evidenzbasierte Therapie von Hyperphosphatämie und Vitamin-D-Mangel
Heine, G. H. (2024) · Nephrologie aktuell · doi:10.1055/a-2415-9576
Chronische Niereninsuffizienz bei Typ-2-Diabetes – die stille Bedrohung einer Multisystemerkrankung
Günes-Altan, M., & Schmieder, R. E. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2318-3452
Afşar, B., Kanbay, M., & Afşar, R. E. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106674
Ansari, M. D., Vishwakarma, A., Quamuddin, M., Aggarwal, M., Khan, H., Jalil, M. F. A., Mahmood, S., Wali, A. F., Talath, S., & El-Tanani, M. (2026) · Frontiers in Medical Technology · doi:10.3389/fmedt.2026.1951734
Schechter, M., Sehtman-Shachar, D. R., Fishkin, A., Mosenzon, O., Cukierman‐Yaffe, T., Sharon, R., Leibowitz, G., Arkadir, D., & Aharon‐Hananel, G. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70315 · Cited by 1
Abomohsen, M., Rifai, M. K., Gadelmawla, A. F., Alghzawi, H. M., Elgendy, M. S., Bakr, H. M., Friedman, A., & Idries, I. Y. M. (2026) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2026.04.001
Silva, J. B. Q., Cebada, A. B., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.011 · Cited by 1
(2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21211-6.00016-2
Lixandru, N., Gaiţă, L., Popescu, S. D., Herascu, A., Timar, B., & Timar, R. Z. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010152
“…in this study, the eGFR decrease was slower than the one expected for a similar population without a GLP-1 RA in their treatment regimen, results comparable to the ones of the FLOW trial, which highlighted a less steep decline in renal function in patients treated with injectable semaglutide [30].”
Alkhateeb, F. S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02716-x
“…with overweight or obesity and established cardiovascular disease without diabetes in SELECT [8], reduced the risk of the primary kidney disease/CV-death composite in patients with T2D and CKD in FLOW [ 17 ], and improved walking capacity in patients with T2D and symptomatic PAD in STRIDE [ 24].”
InfluentialHamilton, A., Thisted, L., Ougaard, M., Hahn, M., Andersen, K., Perens, J., Augustin, R., Bajrami, B., Rist, W., Christensen, M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71387 · Cited by 3
Acute kidney injury and chronic kidney disease in the aging critically ill patient
Gaudry, S., Leaf, D. E., & Guidet, B. (2026) · Intensive Care Medicine · doi:10.1007/s00134-026-08385-7
ПЛЕЙОТРОПНЫЕ ЭФФЕКТЫ АГОНИСТОВ РЕЦЕПТОРОВ ГЛЮКАГОНОПОДОБНОГО ПЕПТИДА‑1
Юрьевич, Ц. В., Lazareva, I. A., Владимировна, Б. Н., Полякова, О. В., & Николаевна, У. С. (2026) · Современные проблемы науки и образования · doi:10.17513/spno.34690
Salim, H., Qureshi, S., Gulsin, G. S., Khan, H. R., Waqas, S. A., McCann, G. P., Garg, A., Shurrab, M., Khunti, K., & Rashid, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71375
Joy, M. S., Gbadegesin, R., Conway, P. T., Chertow, G. M., Liu, K. D., Lim, M. D., Kretzler, M., Bonventre, J. V., & Moderators, O. B. O. T. P. M. W. S. A. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001031
Targeting kidney disease in type 1 diabetes: progress and promise
Muskiet, M. H. A., & Cherney, D. Z. I. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2714265
“Thus, despite well-established and compelling evidence for kidney protection with GLP-1RAs (particularly semaglutide in FLOW [111]) and MHRMs (particularly tirzepatide in SURPASS-CVOT [112]) in T2D [11], the translational applicability of these findings to individuals with T1D and CKD remains…”
Patoulias, D., Karakasis, P., Ruža, I., El‐Tanani, M., & Rizzo, M. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2435426 · Cited by 1
“…treatment with semaglutide 1.0 mg once-weekly versus placebo offered a significant 24% reduction in the risk for the primary composite renal endpoint, also demonstrating a significant reduction in the risk for cardiovascular death by 29%, a finding not previously shown in the SUSTAIN-6 trial [11].”
InfluentialJoshi, D. M. (2026) · Cureus · doi:10.7759/cureus.112135
“In patients with type 2 diabetes and chronic kidney disease, once-weekly semaglutide 1.0 mg reduced clinically important kidney outcomes and death from cardiovascular causes compared with placebo [16].”
InfluentialGLP-1 receptor agonists in obesity treatment: where we are today and what can we expect?
Pichlerová, D. (2026) · Vnitřní lékařství · doi:10.36290/vnl.2026.070
Singh, B., Yaylaci, F., Ali, H. M., Baweja, R., Suarez, M. L. G., & Baweja, R. K. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122407
Targeting the Cardiometabolic Axis: An Integrative Review on Therapeutic Advances
Duru, P., Tasouli-Drakou, V., Ramazani, N., Hartnett, S., Cyrus, T., & Tak, T. (2026) · International Journal of Angiology · doi:10.1055/a-2904-8884
A Future Without Excess Health Care Spending Growth?
Sahni, N. R., Ozisik, M. L., Cutler, D., & Emanuel, E. (2026) · JAMA · doi:10.1001/jama.2026.15970
Kidney disease in patients with HIV
Mejia, S. M., Fischman, C. J., & Sise, M. E. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000941 · Cited by 1
Cho, D. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0002
“30) Secondary outcomes further favored semaglutide, with the mean annual estimated glomerular filtration rate slope being less steep—indicating a slower decline in kidney function—by 1.16 mL/min/1.73 m 2 (p 0.001).”
InfluentialEmerging role of GLP-1RAs in the management of diabetic kidney disease
Bellary, S. (2025) · British Journal of Diabetes · doi:10.15277/bjd.2025.478
Cardio-renal-metabolic syndrome and its management in clinical practice
Šatný, M. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.091
Chronische Nierenkrankheit: Was kann in der Hausarztpraxis getan werden?
Hoffmann, U., Kiel, S., Negnal, M., Chenot, J., & Stracke, S. (2026) · CME · doi:10.1007/s11298-026-4630-3
“Auch Semaglutid bei Diabetes und CKD zeigte eine geringe ARR auf den Endpunkt Nierenversagen [ 16 ].”
The Role of GLP-1R and GIPR Agonism in Heart Failure
Sedrak, P., & Connelly, K. A. (2025) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2025.3138 · Cited by 1
“15 A meta-analysis that combined results from these three trials, in addition to STEP-HFpEF, STEP-HFpEF DM, and SUMMIT, showed the benefit of GLP-1RAs and tirzepatide in reducing worsening HF events across the LVEF spectrum, with acceptable safety outcomes.”
Kardiorenale Medizin in der Pädiatrie – neuer Fokus in Prävention und Therapie
Holle, J. B., Weber, L. T., Sallmon, H., Nordmeyer, J., & Müller, D. M. (2025) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-025-02257-y
Zhou, Z., Fu, L., Chen, D., Yu, P., Xu, G., Wu, Q., Wu, T., & Yang, P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71305
Medical management of obesity: unlocking the potential
Xiang, A. S., & Sumithran, P. (2025) · Climacteric · doi:10.1080/13697137.2025.2455177 · Cited by 1
“Sustainable solutions to inequitable access to obesity care can only be found if pharmaceutical companies, regulators and healthcare payers are willing to negotiate, compromise and prioritize to provide access to those with the greatest need and potential for benefit [34].”
InfluentialIlany, J., Cohen, O., & Gorfine, M. (2025) · Research Square · doi:10.21203/rs.3.rs-6863965/v1
Obesity in Heart Failure: Mechanistic, Diagnostic and Therapeutic Considerations
Pathan, F. K., & Williams, K. (2026) · Cardiac failure review · doi:10.15420/cfr.2026.05
Fadem, S. Z., Bowman, B. T., & Abdel‐Rahman, E. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34069-7.00005-7
Kahlon, B., Gohel, B., Jassemi, S., & Donald, M. (2026) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581251391264
Regulatorik: neue Endpunkte in chronische Nierenerkrankungs(CKD)-Studien
Kronbichler, A., & Ksiazek, S. H. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00874-y
Handelsman, Y., Cheng, A. Y. Y., Fadini, G. P., Kushner, P. R., Bonnet, F., Fioretto, P., KADOWAKI, T., Kanumilli, N., Cos, X., Frese, T., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03618-z
“This is likely due to the more established CKD-specific evidence base available for SGLT2is [10–12], and the fact that FLOW evaluated semaglutide in patients receiving prior guideline-directed standard of care, limiting generalisability to GLP-1 RAs more broadly as a first-line therapy [8, 9].”
InfluentialSelf-citationWada, Y., Toyoda, M., Kobayashi, K., Aoyama, T., Kanamori, A., & Takeuchi, Y. (2026) · Clinical and Experimental Nephrology · doi:10.1007/s10157-026-02845-6
New Insights Into Delaying Renal Progression: Cardiovascular, Renal & Metabolic Medicine
Daoud, R. M., Spencer, S., Desborough, R., & Bhandari, S. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm53144 · Cited by 1
GLP-1 receptor agonists in systemic lupus erythematosus: a scoping review
Sia, R., Ting, E. L., Choy, S., & Sh, O. (2026) · RMD Open · doi:10.1136/rmdopen-2026-007037
Hammer, Y., Arbel, R., Razi, T., Netzer, D., Weinstein, J. M., & Iakobishvili, Z. (2025) · Research Square · doi:10.21203/rs.3.rs-6768681/v1
AlAraibi, A. J., Shakeeb, F. N., Alqatta, T., Sharafeldin, A.-B. K., Dempsey, L., & Butler, A. E. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104994
Shikata, K., Miyamoto, S., Haneda, M., Hosoi, H., Sakamoto, K., Suzuki, Y., Suzuki, D., Ishida, H., Akai, H., Tomino, Y., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70392
“In DNETT-Japan, unlike recent large kidney outcome trials of SGLT2 inhibitors and GLP-1 receptor agonists, 15 – 18 follow-up measurements for eGFR trajectory were discontinued after participants reached the primary outcome, including doubling of serum creatinine.”
Jia, I.-I.-T. T., Bloomfield, G. C., Chen, M. Y., Cunningham, M. H., Wang, A., Daly, S. C., Hinojosa, M. W., Smith, B. R., Nguyen, N. T., Azagury, D. E., et al. (2026) · Surgical Endoscopy · doi:10.1007/s00464-026-12940-0 · Cited by 1
GLP-1 RAs in the heart failure field: Kill many birds with one stone
Christina, A., Andrej, B., & Şener, Y. Z. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132739
Semaglutid bei Herzinsuffizienz mit erhaltener Ejektionsfraktion (HFpEF)
Dürschmied, D., Weidner, K., & Nitschmann, S. (2025) · Die Innere Medizin · doi:10.1007/s00108-024-01844-7
Mehta, P. M., & Rogers, N. M. (2024) · Transplantation · doi:10.1097/tp.0000000000005247
Incretin-Related Drugs and Nutrition
Arai, A., Kobayashi, S., & Okajima, F. (2024) · Nippon Eiyo Shokuryo Gakkaishi · doi:10.4327/jsnfs.77.333
Asmar, A., Akram, M., Sørensen, C. M., Andresen, J. K., & Jensen, B. L. (2026) · Physiological Reports · doi:10.14814/phy2.70940
Hille, H., Schramm, W., & Bounekkar, A. (2026) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-026-00801-5
“For Tirzepatide a HR of 0.58 [27], for Semaglu-tide 0.79 [28] and for Empagliflozin a HR of 0.61 [29] was used.”
InfluentialTian, Z., Willerding, J. M., Schmidt-Ott, K. M., Melk, A., & Schmidt, B. M. W. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104176
Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF
Ceravolo, R., Lucà, F., Gulizia, M. M., Nardi, F., Grimaldi, M., & Gelsomino, S. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.06.015
Kim, H. (2026) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2026.24.e6
Wang, S., DONG, B., & Shen, Z. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01915-y
Confronting the Global Rise of Obesity and Cardiovascular Disease
Spatz, E. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1599
Effect of emerging antiobesity and antidiabetic drugs on atherosclerosis
Armentaro, G., Severini, G., Pastura, C. A., Scarcelli, M. R., Cassano, V., & Sciacqua, A. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04438-3
Chronic kidney disease in metabolic syndrome
Вадимовна, В. С., & Звартау, Н. Э. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6537 · Cited by 5
Malviya, V. (2026) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2026.00050
Tian, X., Ma, X., Song, E., Li, X., Fu, W., He, H., Gao, Z., & Gao, B. (2026) · Translational research · doi:10.1016/j.trsl.2026.07.008
Changement dans la prise en charge de l’obésité : vision du clinicien
Montastier, É. (2026) · Biologie Aujourd hui · doi:10.1051/jbio/2026002
Hasebe, M., Su, C., Yabe, D., & Yoshiji, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71035 · Cited by 1
“…822 participants, were included: LEADER (liraglutide), SUSTAIN-6 (subcutaneous semaglutide), EXSCEL (once-weekly exenatide), Harmony Outcomes (albiglutide), PIONEER 6 (oral semaglu-tide), SELECT (subcutaneous semaglutide), FLOW (subcutaneous semaglutide) and SOUL (oral semaglutide) [4, 18, 37–42].”
GLP-1-based multipharmacology: Biased signaling as a determinant of therapeutic efficacy
Li, W., Yan, J., Zhao, F., & Yang, D. (2026) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2026.07.001
de Sá, J. R. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2026-e008pt
Rethinking endpoints, subgroup analyses, and time-varying treatment in AST-120 CKD research
Li, M. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.08.025
Atif, K., Atif, E., Ali, M., Hassan, M. A., Das, V., Ahmad, A., Fatima, K., Mukhlis, M., Ahmad, D., Zahid, M., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9817293/v1
Li, L., Lui, D. T. W., Fong, C. H.-Y., Mak, J. H., Cheung, C. Y. Y., Xu, A., Tan, K. C. B., Tse, H., Woo, J., Lam, T., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.044588
Spanish Registry of Dialysis and Transplantation: 2023 Report and evolutive analysis
Quiroga, B., Mahíllo, B., Mazuecos, A., Ortiz, A., Troya, M. I., Hernández-Marrero, D., Alemán, S. T., Santiuste, C., Arévalo, O. L. R., Marqués-Vidas, M., et al. (2026) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2026.501510 · Cited by 2
王, 玉. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15123374
Ten Hot Topics in Cardiovascular Risk Management for Chronic Kidney Disease
Marqués, M., Ortíz, A., Romero-González, G. A., Díez, J., Santamaría, R., Puente-García, A., Alcázar, R., de Sequera, P., Górriz, J. L., & Quiroga, B. (2026) · Cardiorenal Medicine · doi:10.1159/000550943 · Cited by 2
Estrategias nutracéuticas dirigidas a la unidad neurovascular en la retinopatía diabética
Fragiotta, S., Ciancimino, C., & Scuderi, G. (2026) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2026.502655
Aggour, Y., & Salguero‐Gómez, R. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1800288
“…such as the GLP-1RAs have not yet been included in Interventions Testing Program analyses, yet their widespread clinical use and emerging evidence of morbidity reduction (Perkovic et al., 2024; Kosiborod et al., 2023; Lincoff et al., 2023; Marso et al., 2016) make them important to contextualise.”
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
Pedagogos, E., Chen, R., Nelson, A. J., Badve, S. V., Rasalam, R. R., & MacIsaac, R. J. (2026) · Internal Medicine Journal · doi:10.1111/imj.70647
Olshvang, D., Harris, C., Chellappa, R. R., Parikh, C., & Santhanam, P. (2026) · medRxiv · doi:10.64898/2026.08.04.26359704
Wallace, H., Abdy, M. E., Anderson, K., Johns, E., Nguyen, T., Scuderi, C. E., Lee, V. W., Tunnicliffe, D. J., & Jun, M. (2026) · Internal Medicine Journal · doi:10.1111/imj.70317
“…and have been shown to improve cardiovascular and kidney outcomes in patients with T2D over and above weight loss or glucose-lowering bene fi ts. 5,21 Currently, GLP1-RAs are available on the PBS in Australia and on the Pharma-ceutical Schedule in New Zealand, with use limited to patients with…”
Cost-effectiveness of multidisciplinary care for patients with chronic kidney disease in Japan
Tomishima, H., Odawara, M., Hatta, T., et al. (2026) · Clinical and Experimental Nephrology · doi:10.1007/s10157-026-02883-0
“…therapy with renin-angiotensin system inhibitors (RASi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), nonsteroidal mineralocorticoid receptor antagonists have recently been shown to be effective for the treatment of diabetic kidney diseases in delaying its progression [ 4–8].”
Interpretation of kidney outcomes during combined SGLT2 inhibitor and GLP-1 receptor agonist therapy
Jansz, T. T., Young, K., Dinsdale, M. M., Cardoso, P., Oram, R. A., & Dennis, J. M. (2026) · The Lancet Primary Care · doi:10.1016/j.lanprc.2026.100201
Liu, C., Hui, Q., Linchangco, G. V., Dabbs‐Brown, A., Zhou, J. J., Joseph, J., Reaven, P. D., Rhee, M. K., Djoussé, L., Cho, K., et al. (2026) · medRxiv · doi:10.64898/2026.04.10.26350615
Marino, G., Alonzo, A., Aiello, A., Fusco, S. A. D., Aquilani, S., & Colivicchi, F. (2025) · Cardiology · doi:10.1093/eurheartjsupp/suaf076.383 · Cited by 1
Yu, Z., Fu, D., Xu, J., Lin, C., Yin, G., Cai, D., Jiang, H., Ling, K., Chen, J., & Zhuo, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1756581 · Cited by 1
Carlson, K., Kaur, J., Gaber, C. E., Reutrakul, S., & Kim, K. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2726017
Recent Updates on the Renoprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists
Choi, H. S., & Bae, E. H. (2025) · Korean Journal of Medicine · doi:10.3904/kjm.2025.100.2.61
“O [ 7 ] S E L E C T [ 8 , 9 ] F L O W [ 10 ] Y e a r”
Nephrology Leadership Through Collaboration to Deliver on CKD Care
Bahrainwala, J. Z., Suffoletto, J.-A., & Brady, B. M. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.01.002
Expert Consensus on the Management of Obesity in Older Adults (2026 Edition)
Pan, Q., & Guo, L. (2026) · Aging Medicine · doi:10.1002/agm2.70105
“Results from the FLOW trial showed that, among patients with T2DM and CKD, including 1767 patients with heart failure at baseline, once-weekly semaglutide 1.0 mg significantly reduced the risk of the major kidney composite endpoint by 24% [79].”
InfluentialBellos, I., Marinaki, S., & Benetou, V. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124840
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.